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■ ORIGINAL ARTICLE ■
Introduction
In Taiwan, the mifepristone–misoprostol method of med-
ical abortion is now growing in popularity as an alter-
native to surgical abortion [1]. The regimen approved
by the United States’ Food and Drug Administration
consists of 600 mg oral mifepristone, followed by 400μg
oral misoprostol 48 hours later, when the gestational
age is less than 49 days [2]. However, a total of 200 mg
mifepristone has been shown to be as effective as the
600 mg dose [3–5]. Hence, many early medical abortion
regimens use a dose of 200 mg mifepristone. Usually,
the standard management of medical abortion failure
has been a dilatation and curettage (D&C). In recent
years, the medical community has begun to question
whether immediate evacuation using surgical interven-
tion is truly necessary in most cases of medical abor-
tion failure. In addition, few trials have described the
salvage therapy after failed medical abortion [6]. Thus,
we studied the efficacy of the vaginal administration of
1,000 μg misoprostol as a salvage therapy rather than
surgical abortion.
Materials and Methods
Initially, 592 women seeking an elective termination of
pregnancy were progressively enrolled. Before under-
going a medical abortion, a patient had to meet the
following criteria: (1) the patient requested a medical
abortion; (2) an intrauterine pregnancy with a gesta-
tional age ≤ 49 days was confirmed using vaginal ultra-
sonography; (3) the patient had signed an agreement
of consent, had been informed of the advantages/risks
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of medical abortion, and understood the necessity of
receiving a surgical abortion if the medical abortion
failed; and (4) the patient promised to attend follow-up
appointments.
No medical abortions were performed on pregnant
women with any of the following exclusion criteria: (1)
allergy to mifepristone or prostaglandins; (2) the pres-
ence of symptoms of threatened abortion; (3) medical
history of heart, respiratory system, kidney, liver or
adrenal disease; (4) medical history of thromboem-
bolism, hypertension, coagulopathy, glaucoma or dia-
betes mellitus; (5) medical history of uterine pathology;
(6) a hemoglobin level of less than 10 g/dL; (7) preg-
nancy with intrauterine device in utero; or (8) active
pelvic infection.
To induce abortion, the women received 200 mg 
of oral mifepristone and 400 μg of oral misoprostol 
48 hours after administration of the mifepristone. If no
expulsion had occurred within 4 hours of taking the
misoprostol, another 200 μg of misoprostol was admin-
istered orally. Individuals were scheduled to return for
follow-up examinations 7 ± 2 days after the second
misoprostol administration, during which transvaginal
ultrasonography was performed. At that time, if the
presence of intrauterine gestational sac was detected,
the subjects were diagnosed with a failed medical abor-
tion. Those women who had expelled the product of
conception then visited the clinic again 14 days later.
The women who failed to achieve a medical abor-
tion according to the above protocol were offered the
choice of a surgical abortion or another attempt at
medical abortion. If the patient elected to take the lat-
ter course, she then received 1,000 μg of misoprostol
vaginally. The participants were given three 500 mg
tablets of acetaminophen that could be taken every 
6 hours if they had lower abdominal pain. The sub-
jects returned 2 days after the vaginal administration
for a follow-up examination. Participants who had not
aborted by this follow-up and still had a gestational sac
were offered a surgical intervention. If the gestational
sac had been expelled, they were scheduled to return for
their follow-up examination 14 days after the expulsion,
at which transvaginal ultrasonography was performed.
Suction curettage was also performed at any time if it
was clinically necessary because of uterine hemorrhage,
incomplete abortion or at the subject’s request.
At each of the participant’s final follow-up visit, she
completed a visual analog scale measuring the amount
of pain experienced during the abortion process [7].
On a 100-mm line, “0” equaled no pain and “100”
represented severe pain.
The primary aim of this trial was to estimate the
complete uterine evacuation rate in women who received
the 1,000 μg vaginal misoprostol regimen. The second-
ary aim included evaluation of the adverse effects of
using such a high-dose misoprostol protocol. This study
received approval from the institutional review board and
written informed consent was obtained from all partic-
ipants. A successful abortion was defined as complete
medical abortion without surgical intervention.
Results
From October 2001 through November 2007, 592
subjects were enrolled for medical abortions. The mean
age of the 592 women was 25.8 years (range, 16–44
years) and the mean gestational age was 43.7 days
(range, 36–49 days). Of these women, 305 (51.5%)
were nulliparous, 92 (15.5%) were primiparous, and
195 (32.9%) were multiparous. Seven days after the
second misoprostol administration, the clinical results
of the medical abortions were determined based on a
complete expulsion rate of 93.1% (551/592). Thus,
there was abortion failure in 41 cases (6.9%) of the
recruited women. Of these 41 women with failed abor-
tions, 10 women were diagnosed as having incomplete
abortions and 31 women had viable pregnancies.
At this point, the 10 women with incomplete abor-
tions and four with viable pregnancies requested D&C.
Among the remaining 27 women, all had persistent
pregnancies and 16 had embryonic heart beats that
could be detected. The demographics of these 27
women who enrolled in the study are listed in Table 1.
This group received 1,000 μg of misoprostol vaginally.
During the follow-up, expulsion of the products of
conception occurred at 2 days after administration of
misoprostol in 25 (92.6%) of the women. The remain-
ing two women were recommended to receive D&C
because of the presence of intrauterine gestational
sacs. When examined after the 2 weeks of follow-up,
abortion had been successfully induced in 24 of the 
25 women, while one patient requested D&C because
of the presence of persistent bleeding. The histopatho-
logic findings revealed the presence of conception
products. Overall, 24 (88.9%) participants had complete
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Table 1. Demographics of study population (n = 27)
Mean age (yr) 25.8 (range, 16–44)
Mean gestational age (d) 45.8 (range, 42–53)
Parity, n (%)
0 14 (51.9)
1 7 (25.9)
2 6 (22.2)
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abortions after the high-dose misoprostol treatment
regimen. The number and percentage of the efficacious
abortion and reasons for surgical intervention are listed
in Table 2.
With the 1,000 μg vaginal misoprostol abortion
regimen, the mean time from drug administration to
bleeding was 2.5 hours (range, 1.5–4.5 hours), and the
time to expulsion of the products of pregnancy was 
4 hours (range, 3–8 hours). The mean duration of bleed-
ing was 12.5 days (range, 8–22 days). The adverse
effects of the treatment included pelvic pain (81.8%),
diarrhea (70.3%), shivering (55.6%), fever (48.1%), nau-
sea (44.4%), vomiting (25.9%), and dizziness (7.4%). The
mean level of pain reported on the post-questionnaire
was 60 mm (range, 10–90 mm). The maximum body
temperature recorded was 38.2°C and the mean number
of episodes of vomiting was 2.5 (range, 1–6 episodes).
However, most adverse effects were mild to moderate
and did not require treatment except for analgesics.
Table 3 provides details of the women’s reports of the
side effects experienced following vaginal misoprostol
administration. During the treatment course involving
the administration of 1,000 μg misoprostol as a sal-
vage therapy, no patient became infected, had severe
hemorrhaging or had any need for blood transfusion.
Discussion
In regard to medical abortion, since vaginal bioavailabil-
ity of misoprostol is three times greater than the drug’s
oral bioavailability, vaginal administration of misopros-
tol is more efficacious than oral administration. Citing
several papers, Kahn et al [3] asserted that the oral
administration of misoprostol had an incomplete abor-
tion rate of 6.4%, while that for vaginal administration
was 2.1%. Thus, vaginal administration of misoprostol
was more efficacious than oral administration.
Generally, the success rate of medical abortion in
early pregnancy has been reported to be about 95%
[8,9]. If medical abortion fails, surgery is usually per-
formed to terminate the pregnancy. However, in a 2001
study involving 300 women with a pregnancy duration
of 6–9 weeks, Carbonell and colleagues [10] reported
a success rate of 93% using 1,000 μg of misoprostol
administered vaginally, a procedure that could be re-
peated every 24 hours up to three times. In their report,
no patient needed to receive a blood transfusion or be
treated for pelvic infection. The authors recommended
that 1,000 μg misoprostol administered vaginally could
be a valid method for the termination of pregnancies
of up to 9 weeks of gestation. Therefore, we adopted
vaginal administration of misoprostol and used the high
1,000 μg misoprostol dose as a salvage therapy after
medical abortion failure. In our study, the overall suc-
cessful expulsion rate reached 88.9%, so most women
with failed abortions were able to avoid surgical inter-
vention. Furthermore, excessive hemorrhaging and/or
pelvic infections did not occur in this trial.
The use of misoprostol as a salvage therapy has
undergone studies for failed medical abortion. Li et al
[6] reported that 1,000 μg of vaginal misoprostol led
to complete abortion in 10 of 11 (90.9%) early pregnant
women after medical abortion failure with acceptable
side effects. In another report, Li et al [11] described
that supplementary use of 1,000 μg misoprostol vagi-
nally may be an alternative when terminating an early
pregnancy in association with a myomatous uterus, 
if the conventional combination of mifepristone and
misoprostol failed. These studies suggest a high safety
profile for high-dose misoprostol regimen after failed
medical abortion. In our present trial, which included
the administration of 1,000 μg vaginal misoprostol, we
also found that most of the adverse effects were mild
to moderate and did not require any treatment except
pain killers.
In conclusion, if early medical abortion fails, the
vaginal administration of 1,000 μg of misoprostol may
be considered instead of surgical abortions, with toler-
able side effects. Although few reports exist on medical
abortions using high doses of vaginal misoprostol, the
surgical risks of anesthesia, hemorrhaging, infection and
perforation can be avoided when vaginal misoprostol
is used.
Table 2. Efficacy (n = 27)
Success rate (%) 88.9
Failure rate (%) 11.1
Surgical intervention (%)
Viable pregnancy 7.4
Patient’s request 3.7
Table 3. Number and percentage of side effects (n = 27)
Side effects n (%)
Pelvic pain 22 (81.8)
Diarrhea 19 (70.3)
Shivering 15 (55.6)
Fever 13 (48.1)
Nausea 12 (44.4)
Vomiting 7 (25.9)
Dizziness 2 (7.4)
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